David Shantz

Chief Marketing Officer

David has been responsible for the development of Wellesley Pharmaceuticals as a company and Nocturol as a product from the earliest stages of development. From development of the initial fundraising, investor outreach and brand development, through subsequent follow on rounds and through all aspects of the company’s global presence.

Previously, David has had a key role in the development of numerous venture-backed start-ups, including:

CoAlign – the first expandable inter-body device for lower lumbar procedures (acquired by Stryker)

ZKR Ortho – Treatment for osteoarthritis and cartilage degeneration (venture funded)

IntroVein – Vascular Access (FDA approved in hospital evals)

Kalrea – vertical farming technology $120M in PE capitalization and publicly traded on NASDAQ